Cornelia Quadt
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Heat shock proteins research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Glutathione Transferases and Polymorphisms
Most-Cited Works
- → Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor(2014)575 cited
- → Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study(2018)432 cited
- → mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer(2013)347 cited
- → Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer(2018)257 cited
- → PI3K inhibitors as new cancer therapeutics: implications for clinical trial design(2016)230 cited
- → NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models(2008)222 cited
- → First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors(2013)158 cited
- → 89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922(2010)112 cited
- → T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct(2005)103 cited
- → 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft(2009)98 cited